Subjective and Objective Results of Radiofrequency Ablation in Drug-Resistant Allergic Rhinitis Based on a 12-Month Follow-up Study.
- Author:
Seon Sook HAN
1
;
Seung Joon LEE
;
Jun Yeon WON
;
Hyun Kyung CHOI
;
Eui Cheol NAM
Author Information
1. Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.
- Publication Type:Original Article
- Keywords:
Allergic rhinitis;
Radiofrequency;
Long-term effects
- MeSH:
Follow-Up Studies;
Humans;
Nasal Obstruction;
Prospective Studies;
Pruritus;
Rhinitis;
Rhinitis, Allergic, Perennial;
Rhinometry, Acoustic;
Sneezing
- From:Journal of Rhinology
2009;16(2):110-115
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND AND OBJECTIVES: Allergic rhinitis is a common condition that has been treated using various methods. Nevertheless, it remains an intractable condition in some cases. We evaluated the long-term efficacy of radiofrequency ablation (RFA) therapy for drug-resistant allergic rhinitis. MATERIALS AND METHODS: Eighteen patients with allergic rhinitis were enrolled in this prospective interventional study. Their subjective symptoms and objective findings were assessed using a visual analogue scale and acoustic rhinometry before and after RFA therapy. Postoperative follow-up was carried out at 1, 3, 6, and 12 months. RESULTS: Nasal obstruction and rhinorrhea were improved significantly (p<0.001 and p=0.015, respectively), and these effects continued for 12 months after RFA therapy. However, the effects on nasal itching and sneezing did not last throughout the year of the study. Patients' overall satisfaction scores declined at 12 months. On acoustic rhinometry, the minimal cross-sectional area and the total nasal volume did not show improvement, and there were no correlations with the subjective symptoms. Most of the complications associated with the RFA procedure were minimal and resolved within 4 weeks. CONCLUSION: RFA is a safe, simple, and effective procedure for relieving nasal obstruction and rhinorrhea for at least 12 months in drug-resistant allergic rhinitis.
